Abstract | PURPOSE: METHODS: RESULTS: The complete response rate of study group was significantly better than control group (78.3% vs 50%, P=0.035). The difference in median progression-free survival (PFS) in the two groups was statistically significan (not reach vs 27 months, P=0.037). Multivariate comparisons of prognostic factors in the two groups indicated that both the Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) stage and combined nimotuzumab treatment affected PFS (P<0.05). Although generally tolerable, grade 3-4 toxicities including leukopenia (P=0.025) and hemoglobin (P=0.026) reduction were more frequent in the control group than those in the study group. CONCLUSION: These data suggest that combining nimotuzumab with CCRT for the treatment of LACC resulted in extended PFS and higher complete remission rates, without an increased incidence of adverse events.
|
Authors | Wenli Chen, Tao Li, Jian Wang, Long Liang, Dandan Huang, Gaoshu Yan, Ye Tian, Xiaoli Zhang, Wei Zhang |
Journal | Cancer management and research
(Cancer Manag Res)
Vol. 11
Pg. 8157-8165
( 2019)
ISSN: 1179-1322 [Print] New Zealand |
PMID | 31564975
(Publication Type: Journal Article)
|
Copyright | © 2019 Chen et al. |